AAVantgarde Completes Enrollment in LUCE-1 Phase 1/2 Trial of AAVB-081 for Usher Syndrome Type 1B-Associated Retinitis Pigmentosa
AAVantgarde Bio announced completion of enrollment in the LUCE-1 Phase 1/2 first-in-human clinical trial evaluating AAVB-081 on January 15-17, 2026.
LUCE-1 is a multicenter, open-label, dose-escalation study assessing safety, tolerability, and preliminary efficacy of single subretinal AAVB-081 administration.
The trial enrolled 15 adults aged 18-60 with retinitis pigmentosa due to MYO7A mutations in Usher syndrome type 1B (USH1B).
AAVB-081 is a dual-AAV gene therapy targeting the root cause of USH1B vision loss.
CEO Dr. Natalia Misciattelli called it a key milestone, thanking patients and staff.
Prof. Michaelides from Moorfields Eye Hospital highlighted its significance for patients.
AAVantgarde is also recruiting for the CELESTE trial in Stargardt disease, with updates expected in 2026.
No approved treatments exist for USH1B retinal degeneration.